Broad‐Spectrum Engineered Multivalent Nanobodies Against SARS‐CoV‐1/2
Advanced Science · 2024
DOI: 10.1002/advs.202402975 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2024. Verfasst von Zhihong Wang und 17 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing, 100850, P. R. China. Hauptthemen laut MEDLINE: Single-Domain Antibodies, SARS-CoV-2, COVID-19, Antibodies, Viral. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Beijing Nova Program.
Abstract (Originalsprache)
SARS‐CoV‐2 Omicron sublineages escape most preclinical/clinical neutralizing antibodies in development, suggesting that previously employed antibody screening strategies are not well suited to counteract the rapid mutation of SARS‐CoV‐2. Therefore, there is an urgent need to screen better broad‐spectrum neutralizing antibody. In this study, a comprehensive approach to design broad‐spectrum inhibitors against both SARS‐CoV‐1 and SARS‐CoV‐2 by leveraging the structural diversity of nanobodies is proposed. This includes the de novo design of a fully human nanobody library and the camel immunization‐based nanobody library, both targeting conserved epitopes, as well as the development of multivalent nanobodies that bind nonoverlapping epitopes. The results show that trivale B11‐E8‐F3, three nanobodies joined tandemly in trivalent form, have the broadest spectrum and efficient neutralization activity, which spans from SARS‐CoV‐1 to SARS‐CoV‐2 variants. It is also demonstrated that B11‐E8‐F3 has a very prominent preventive and some therapeutic effect in animal models of three authentic viruses. Therefore, B11‐E8‐F3 has an outstanding advantage in preventing SARS‐CoV‐1/SARS‐CoV‐2 infections, especially in immunocompromised populations or elderly people with high‐risk comorbidities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing, 100850, P. R. China.
- Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun, 130122, P. R. China.
- Joint National Laboratory for Antibody Drug Engineering, the First Affiliated Hospital, Henan University, Kaifeng City, Henan, 475004, P. R. China.
- Hunan Normal University School of medicine, Changsha, Hunan, 410200, P. R. China.
ORCID-Profile: Longlong Luo
Förderung
- National Natural Science Foundation of China
- Beijing Nova Program
Zitieren
APA
Wang, Z., Shi, Z., Liao, X., Quan, G., Dong, H., Zhao, P., Zhou, Y., Shi, N., Wang, J., Wu, Y., Qiao, C., Li, X. Y., Zhang, R., Wang, Z., Wang, T., Gao, X., Feng, J., & Luo, L. (2024). Broad‐Spectrum Engineered Multivalent Nanobodies Against SARS‐CoV‐1/2. Advanced Science. https://doi.org/10.1002/advs.202402975
Vancouver
Wang Z, Shi Z, Liao X, Quan G, Dong H, Zhao P, et al. Broad‐Spectrum Engineered Multivalent Nanobodies Against SARS‐CoV‐1/2. Advanced Science. 2024. doi:10.1002/advs.202402975
BibTeX
@article{Wang2024,
author = {Wang, Zhihong and Shi, Zhuangzhuang and Liao, Xiaochen and Quan, Guiqi and Dong, Hui and Zhao, Pinnan and Zhou, Yangyihua and Shi, Ning and Wang, Jie and Wu, Yahui and Qiao, Chunxia and Li, Xin Ying and Zhang, Ran and Wang, Zekun and Wang, Tiecheng and Gao, Xiang and Feng, Jiannan and Luo, Longlong},
title = {Broad‐Spectrum Engineered Multivalent Nanobodies Against SARS‐CoV‐1/2},
journal = {Advanced Science},
year = {2024},
doi = {10.1002/advs.202402975}
}
EUVIMED